Investor Backing & Capital Strength:
Evidence indicates a $55M Series B in 2026 brought cumulative funding above $73M to accelerate hiring, R&D, and platform adoption. This capital position supports scaling operations and product development.
Strong Revenue Growth:
Company materials state revenue increased 4× in the 12 months prior to April 2024, with earlier periods citing 24× growth and expectations to more than double in 2022. These signals indicate rapid top-line expansion, though current figures are not independently audited.
Product Line Growth:
The offering has expanded beyond payment integrity into utilization management and appeals while launching AI agents for DRG validation, readmissions, and emergency-department reviews. This broadening scope increases relevance across health‑plan claims workflows.
